News

Mankind Pharma shares gain 3% on acquiring Rivotril brand from Roche for Indian marketMankind Pharma Ltd shares surged nearly 3% after acquiring the Rivotril brand from Roche for the Indian market, strengthening its presence in CNS therapies. The stock rose to ₹2,125.10.By Gareema Bangad  March 18, 2026, 11:18:01 AM IST (Published)2 Min ReadShares of Mankind Pharma Ltd surged nearly 3% on Wednesday, March 18, after it announced the acquisition of the Rivotril brand for the Indian market from Roche.

In a press release filed with the exchanges, the company said it has secured exclusive rights to manufacture, market and distribute Rivotril in India, in a move that will strengthen its presence in the chronic and central nervous system (CNS) therapies segment.

Rivotril is an innovator formulation of clonazepam and is widely prescribed for neurological and psychiatric conditions.

Mankind Pharma said the acquisition adds a well-established brand with a strong clinical legacy and specialist recall to its portfolio, complementing its existing neuro/CNS offerings.

Atish Majumdar, Senior President, Sales & Marketing, Mankind Pharma Specialty Business, said, "This acquisition is aligned with our strategic focus on strengthening our presence in chronic therapies and speciality therapies."

Citing strong opportunities through the platform, he said, "Leveraging our large field force and nationwide distribution network, we are well-positioned to build the brand and support physicians in delivering better outcomes for patients across India.”

Mankind Pharma added that the deal also creates opportunities for future line extensions in the CNS segment, helping address evolving patient and physician needs.

Mankind Pharma currently engages with over five lakh doctors and has a strong presence across both urban and semi-urban markets, supporting deeper penetration of its speciality portfolio.

For the December quarter, the company posted a 7.5% year-on-year growth in net profit to ₹408.7 crore from ₹380.2 crore in Q3FY25. Revenue rose 11.5% YoY to ₹3,567 crore from ₹3,198 crore last year. EBITDA increased 12.7% to ₹919.6 crore from ₹816.2 crore, and EBITDA margin stood at 25.8%, compared with 25.5% in the same quarter last year.

Following the announcement, shares of the company gained nearly 2.75% to ₹2,125.10. The stock has declined 19.60% in the last six months.Continue ReadingTagsMankind PharmaPharma companiesshare market today